← Back to Home

Blocking cellular stress signaling protects β cells in mice and human islets

A pathway that normally helps cells cope with stress may instead promote β-cell death when overactivated. Blocking its signaling can reduce cell loss, but animal experiments also show that preserving cells remains a step removed from restoring blood glucose control.

By SURL BioNews

As insulin-producing β cells gradually die under sustained strain, the body's ability to regulate blood glucose also weakens. A research team at Weill Cornell Medicine identified a stress signaling chain involved in this process and found that blocking part of it could reduce β-cell death in mice and donor-derived human islet cells, offering a new research direction for preserving insulin production capacity.

The study, conducted by Laura Alonso, Rohit Sharma and colleagues, was published in the Journal of Clinical Investigation on August 3, 2026, and highlighted by the institution in October. It focused on the “unfolded protein response”: when the endoplasmic reticulum becomes overloaded with protein processing, cells activate this mechanism to adjust protein production and support proper folding. However, if this normally stress-relieving response remains out of control, it may also drive cells toward death.

The team began with GRP78, a protein that helps maintain balance in this system. When researchers removed GRP78 from mouse β cells, the cells developed an overactive stress response, accompanied by β-cell loss, severe insulin deficiency and diabetes. Further analysis indicated that the kinase activity of IRE1α activates JNK signaling, which then connects to downstream p53 to promote apoptosis.

Blocking this signaling chain had a protective effect. Inhibiting JNK reduced β-cell death in two mouse models of diabetes related to endoplasmic reticulum stress. One lacked GRP78, while the other, the Akita mouse, accumulated misfolded proinsulin because of an insulin gene mutation. In ex vivo cultures of human donor islets, separately inhibiting JNK or p53 after reducing GRP78 also reduced β-cell apoptosis.

However, keeping cells alive does not necessarily fully restore their function. After 28 days of JNK inhibition in Akita mice, β-cell mass increased, but blood glucose did not return to normal, and circulating insulin improved only slightly. This gap suggests that reducing cell death alone may be insufficient to reverse diabetes if defects in insulin production, secretion or action persist.

The findings also cannot be directly applied to patients in general. Removing GRP78 creates an artificially intense stress condition that may not fully reproduce the course of common forms of diabetes. The study used bulk RNA sequencing, making it difficult to distinguish changes in different cell types, and the adenoviral tool used to reduce GRP78 may itself add cellular stress. Human islet cultures provide supporting evidence across species, but they still do not establish that treatment would be effective in humans.

The drug itself is another hurdle before clinical use. The institution noted that the JNK inhibitor used in the experiments acts on multiple forms of JNK and raises concerns about impaired kidney function, so inhibitors better suited to clinical use still need to be identified. The team next plans to test the protective effect in other diabetes models, including those involving a high-fat diet. The key question is whether β cells can be safely preserved while also retaining sufficient insulin function.

References

  1. Weill Cornell Medicine
  2. The Journal of Clinical Investigation
  3. Weill Cornell Medicine Center for Metabolic Health